Akebia Therapeutics, Inc. AKBA
0.57 USD +0.03 (+5.89%)
At closeNov 11, 2026, 7:30 PM EST
0.56 -0.01 -2.13%
After hours · Nov 11, 7:30 PM ET
0.5153 Day range 0.5792
0.361 52-week range 1.89
- YTD
- -64.37%
- 1 year
- -68.30%
News
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com HC Wainwright & Co. Maintains Buy on Akebia Therapeutics, Lowers Price Target to $4 HC Wainwright & Co. analyst Matthew Caufield maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $6 to $4.
seekingalpha.com Akebia Therapeutics, Inc. (AKBA) Q3 2026 Earnings Call Transcript Akebia Therapeutics, Inc. ( AKBA ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Mercedes Carrasco - Senior Director of Investor & Corporate Communications John Butler -…
benzinga.com BTIG Maintains Buy on Akebia Therapeutics, Lowers Price Target to $3 BTIG analyst Julian Harrison maintains Akebia Therapeutics (NASDAQ:AKBA) with a Buy and lowers the price target from $4 to $3.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Lakewood-Amedex (NASDAQ:LABT) shares moved upwards by 237.6% to $0.65 during Thursday's regular session. ADMA Biologics (NASDAQ:ADMA) stock increased by 25.62% to $13.16. The market value of…
marketbeat.com What Akebia Therapeutics (AKBA) Said on Its Q3 Earnings Call Akebia Therapeutics NASDAQ: AKBA reported lower third-quarter revenue and a net loss as sales of its kidney disease drug Auryxia fell and inventory reductions limited revenue growth for its anemia…
zacks.com Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
benzinga.com Akebia Therapeutics Q3 2026 Earnings Call Transcript Akebia Therapeutics (NASDAQ:AKBA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Akebia Therapeutics Q3 EPS $(0.05) Misses $(0.04) Estimate, Sales $36.900M Miss $46.941M Estimate Akebia Therapeutics (NASDAQ:AKBA) reported quarterly losses of $(0.05) per share which missed the analyst consensus estimate of $(0.04) by 25 percent. The company reported quarterly sales of $36.900…
globenewswire.com Akebia Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025
globenewswire.com Akebia Therapeutics Reports Positive Topline Data from VOCAL Trial Showing Vadadustat Dosed TIW Met Primary Endpoint of Non-Inferiority to ESA in Maintaining Hemoglobin WALTHAM, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
globenewswire.com Akebia Therapeutics to Report Third Quarter 2026 Financial Results and Discuss Recent Business Highlights WALTHAM, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2026, on…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Surgery Partners (NASDAQ:SGRY) shares moved upwards by 46.9% to $23.14 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. SciSparc (NASDAQ:SPRC)…
benzinga.com Akebia Therapeutics Reports Data From Vafseo Outcomes In Center Experience Study At American Society Of Nephrology Kidney Week 2026 In Patients With Treated With Vadadustat Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease announced that U.S. Renal Care (USRC), the nation’s…
globenewswire.com U.S. Renal Care Presents Analysis of VOICE Trial Demonstrating Favorable Safety Outcomes for Patients Treated with Vadadustat Versus an ESA During a Late-Breaking Session at American Society of Nephrology Kidney Week Vadadustat demonstrated a clinically meaningful safety outcome benefit in U.S. patients with anemia due to CKD on dialysis utilizing TIW dosing regimen Vadadustat demonstrated a clinically meaningful…
globenewswire.com Akebia Therapeutics to Conduct Investor Meetings at the Virtual U.S. Bancorp I BTIG Kidney Health Forum WALTHAM, Mass., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
globenewswire.com Akebia Therapeutics Announces Late-Breaking VOICE Trial Presentation and Posters on Akebia's Rare Kidney Pipeline at ASN Kidney Week 2026 WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
globenewswire.com Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) WALTHAM, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…- benzinga.com BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.
benzinga.com Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is expected in 2027
globenewswire.com Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy Initial data is expected in 2027 WALTHAM, Mass., Sept. 14, 2026 (GLOBE…- benzinga.com WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5 WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.
globenewswire.com Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney…
globenewswire.com Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 107.8% to $1.39 during Thursday's regular session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock increased by 86.9% to $1.25 during Thursday's pre-market session. The company's market cap stands at $4.3 million. Ensysce Biosciences (NASDAQ:ENSC)…
benzinga.com Western Digital, Applovin, Zillow Group And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session U.S. stock futures mixed, Dow up 100+ points. Western Digital falls after earnings beat expectations but lowers guidance. Other stocks dip in pre-market.
benzinga.com Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser…
seekingalpha.com Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript Akebia Therapeutics, Inc. (AKBA) Q2 2026 Earnings Call Transcript
zacks.com Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to break-even earnings per share a year ago.
marketbeat.com Akebia Therapeutics Q2 Earnings Call Highlights Akebia Therapeutics NASDAQ: AKBA reported second-quarter revenue growth for its Vafseo anemia treatment while highlighting an interim clinical result from the VOICE study and progress across its…
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 31.4% to $0.88 during Wednesday's after-market session. The company's market cap stands at $4.2 million. Caris Life Sciences…
globenewswire.com Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights Q2 2026 Vafseo® (vadadustat) net product revenues grew to $21.3 million ; more than 10,500 p atients now on therapy Advancement of rare kidney disease pipeline continues with initiation of Phase 2…
globenewswire.com Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
globenewswire.com Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases CAMBRIDGE, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease,…
globenewswire.com Akebia Therapeutics to Report Second Quarter 2026 Financial Results and Discuss Recent Business Highlights CAMBRIDGE, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2026 on…
benzinga.com Earnings Scheduled For February 26, 2026 - benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com Earnings Scheduled For November 10, 2025 
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Mondelez International, Stride, Varonis Systems And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session 
benzinga.com Why Teradyne Shares Are Trading Higher By More Than 20%; Here Are 20 Stocks Moving Premarket 
benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session - benzinga.com Earnings Scheduled For August 7, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com Earnings Scheduled For May 8, 2025
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session